Jetrea®

	Next higher product group	ocriplasmin
	Status	2013-01-14 sales start
	Organisation	ThromboGenics Inc. (subsidiary of Oxurion N.V.)
	Group	Oxurion (Group)
	Organisation 2	ThromboGenics N.V. (Euronext Brussels: THR)
	Today	Oxurion N.V. (Euronext Brussels: OXUR)
	Group	Oxurion (Group)

Record changed: 2023-07-10

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Jetrea®

[1] Oxurion N.V.. (9/10/18). "Press Release: Oxurion NV Announces New Euronext Brussels Stock Ticker “OXUR” and Launch of New Website". Leuven....
[2] ThromboGenics N.V.. (3/15/18). "Press Release: ThromboGenics Business Update – FY 2017". Leuven....
[3] ThromboGenics N.V.. (1/26/18). "Press Release: Novartis Pharma AG Holding 5.69% of ThromboGenics Equity Capital". Leuven....
[4] ThromboGenics N.V.. (10/20/17). "Press Release: ThromboGenics Business Update – Q3 2017". Leuven....
[5] ThromboGenics N.V.. (9/28/17). "Press Release: ThromboGenics Successfully Introduces New »Already-Diluted« Formulation of Jetrea (ocriplasmin) in the US". Leuven....
[6] ThromboGenics N.V.. (9/18/17). "Press Release: ThromboGenics Regains Global Rights to Jetrea (ocriplasmin)". Leuven....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]